The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

Abu Dhabi Public Health Centre (ADPHC) has vaccinated nearly 300,000 people across Abu Dhabi, Al Ain Region, and Al Dhafra with the seasonal flu vaccine as part of its 2024–2025 campaign, a 45 percent ...

Onradivir significantly shortens recovery time in adults with uncomplicated influenza A. Read more. Learn more.

An 82-year-old on haemodialysis tests HIV-positive 7 months in, only for PCR to be negative, implicating flu shot antibody ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA (clesrovimab-cfor) , a ...

South Africa will proceed with its long-awaited vaccination strategy against Highly Pathogenic Avian Influenza (HPAI), Deputy ...

Explore why Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams.

Infectious disease clinicians raised alarm that proposed cuts to Medicaid could affect ID-related services, not only among ...